Eli Lilly and Company (NYSE:LLY) Shares Sold by ORBA Wealth Advisors L.L.C.

ORBA Wealth Advisors L.L.C. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 397 shares of the company’s stock after selling 17 shares during the period. ORBA Wealth Advisors L.L.C.’s holdings in Eli Lilly and Company were worth $352,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in LLY. Capital Planning LLC purchased a new stake in Eli Lilly and Company during the 1st quarter valued at about $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in Eli Lilly and Company during the 1st quarter worth approximately $6,916,000. M&G Plc acquired a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $8,896,000. HighPoint Advisor Group LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $9,878,000. Finally, Leo Wealth LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $3,355,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 1.2 %

Shares of LLY stock traded up $10.98 during trading hours on Friday, hitting $921.67. The company had a trading volume of 756,332 shares, compared to its average volume of 3,001,753. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market capitalization of $875.98 billion, a PE ratio of 113.34, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company’s fifty day moving average is $908.28 and its 200 day moving average is $851.21. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. BMO Capital Markets boosted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Citigroup began coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective on the stock. Jefferies Financial Group lifted their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.